Puche Juan E, García-Fernández María, Muntané Jordi, Rioja José, González-Barón Salvador, Castilla Cortazar Inma
Department of Medical Physiology, School of Medicine, University CEU-Universidad San Pablo, Boadilla del Monte, 28668, Madrid, Spain.
Endocrinology. 2008 May;149(5):2620-7. doi: 10.1210/en.2007-1563. Epub 2008 Feb 14.
Serum IGF-I levels decline with age. We have recently reported that in aging rats the exogenous administration of IGF-I restores IGF-I circulating levels and age related-changes, improving glucose and lipid metabolisms, increasing testosterone levels and serum total antioxidant capability, and reducing oxidative damage in the brain and liver associated with a normalization of antioxidant enzyme activities. Understanding that mitochondria are one of the most important cellular targets of IGF-I, the aims of this study were to characterize mitochondrial dysfunction and study the effect of IGF-I therapy on mitochondria, leading to cellular protection in the following experimental groups: young controls, untreated old rats, and aging rats treated with IGF-I. Compared with young controls, untreated aging rats showed an increase of oxidative damage in isolated mitochondria with a mitochondrial dysfunction characterized by: depletion of membrane potential with increased proton leak rates and intramitochondrial free radical production, and a significant reduction of ATPase and complex IV activities. In addition, mitochondrial respiration from untreated aging rats was atractyloside insensitive, suggesting that the adenine nucleotide translocator was uncoupled. The adenine nucleotide translocator has been shown to be one of the most sensitive locations for pore opening. Accordingly, untreated aging rats showed a significant overexpression of the active fragment of caspases 3 and 9. IGF-I therapy corrected these parameters of mitochondrial dysfunction and reduced caspase activation. In conclusion, these results show that the cytoprotective effect of IGF-I is closely related to a mitochondrial protection, leading to reduce free radical production, oxidative damage, and apoptosis, and to increased ATP production.
血清胰岛素样生长因子-I(IGF-I)水平会随着年龄增长而下降。我们最近报道,在衰老大鼠中,外源性给予IGF-I可恢复IGF-I的循环水平以及与年龄相关的变化,改善葡萄糖和脂质代谢,提高睾酮水平和血清总抗氧化能力,并减少大脑和肝脏中的氧化损伤,同时使抗氧化酶活性恢复正常。鉴于线粒体是IGF-I最重要的细胞靶点之一,本研究的目的是表征线粒体功能障碍,并研究IGF-I治疗对线粒体的影响,从而在以下实验组中实现细胞保护:年轻对照组、未治疗的老年大鼠以及接受IGF-I治疗的衰老大鼠。与年轻对照组相比,未治疗的衰老大鼠分离的线粒体中氧化损伤增加,线粒体功能障碍的特征为:膜电位耗竭,质子泄漏率增加和线粒体内自由基产生增加,以及ATP酶和复合物IV活性显著降低。此外,未治疗的衰老大鼠的线粒体呼吸对苍术苷不敏感,这表明腺嘌呤核苷酸转位酶解偶联。腺嘌呤核苷酸转位酶已被证明是孔开放最敏感的位置之一。因此,未治疗的衰老大鼠显示半胱天冬酶3和9的活性片段有显著过表达。IGF-I治疗纠正了这些线粒体功能障碍参数并减少了半胱天冬酶激活。总之,这些结果表明IGF-I的细胞保护作用与线粒体保护密切相关,从而减少自由基产生、氧化损伤和细胞凋亡,并增加ATP生成。